Changing the cardiovascular prevention game. Results from a large clinical trial may mean a new era of super-low LDL targets and anti-inflammatory strategies.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000187:drug effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007249:Inflammation
D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein